Switch theme
Sign up to access all valuation multiples
Green Cross Holdings Corp manufactures and sells medicines and medical supplies. The company's products include Plasma Derivatives, Vaccines, Prescription Drugs and Over-the-counter Drugs. Some of the drugs offered by the company comprise of Acustop Cataplasma, Zenol Cool Type, Green-VIII inj and Hunterase.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GC Biopharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, GC Biopharma achieved revenue of $1.5B and an EBITDA of $149M.
GC Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GC Biopharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.5B | XXX | XXX | XXX |
| Gross Profit | $488M | $421M | XXX | XXX | XXX |
| Gross Margin | 34% | 27% | XXX | XXX | XXX |
| EBITDA | $46.7M | $149M | XXX | XXX | XXX |
| EBITDA Margin | 3% | 10% | XXX | XXX | XXX |
| Net Profit | $22.9M | -$37.8M | XXX | XXX | XXX |
| Net Margin | 2% | -2% | XXX | XXX | XXX |
| Net Debt | $501M | $625M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 25, 2025, GC Biopharma's stock price is KRW 13813 (or $10).
GC Biopharma has current market cap of KRW 627B (or $438M), and EV of KRW 1.67T (or $1.2B).
See GC Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $438M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 25, 2025, GC Biopharma has market cap of $438M and EV of $1.2B.
GC Biopharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate GC Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for GC Biopharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 7.8x | XXX | XXX | XXX |
| P/E | 26.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -11.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGC Biopharma's NTM/LTM revenue growth is n/a
GC Biopharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, GC Biopharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate GC Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for GC Biopharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 218% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 29% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GC Biopharma acquired XXX companies to date.
Last acquisition by GC Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . GC Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was GC Biopharma founded? | GC Biopharma was founded in 1967. |
| Where is GC Biopharma headquartered? | GC Biopharma is headquartered in South Korea. |
| Who is the CEO of GC Biopharma? | GC Biopharma's CEO is Mr. Il-Seop Heo. |
| Is GC Biopharma publicy listed? | Yes, GC Biopharma is a public company listed on KRX. |
| What is the stock symbol of GC Biopharma? | GC Biopharma trades under 005250 ticker. |
| When did GC Biopharma go public? | GC Biopharma went public in 1978. |
| Who are competitors of GC Biopharma? | Similar companies to GC Biopharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of GC Biopharma? | GC Biopharma's current market cap is $438M |
| What is the current revenue growth of GC Biopharma? | GC Biopharma revenue growth between 2023 and 2024 was 7%. |
| Is GC Biopharma profitable? | Yes, GC Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
